High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes

Journal of Biomolecular Screening

Volumn 19, Issue 9, 2014, Pages 1266-1274

  Seegers, Nicole ^a   Van Doornmalen, Antoon M ^a   Uitdehaag, Joost C M ^a   De Man, Jos ^a   Buijsman, Rogier C ^a   Zaman, Guido J R ^a  

^a Netherlands Translational Research Center BV   (Netherlands)

Author keywords

cancer immunotherapy; high throughput screening; indoleamine 2,3 dioxygenase; N formyl kynurenine; neurodegenerative disease; tryptophan; tryptophan 2,3 dioxygenase

Indexed keywords

BETA CARBOLINE; COMPOUND 51; ENZYME INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; KYNURENINE; N FORMYLKYNURENINE; NTRC 0672 0; NTRC 0820 0; NTRC 0989 0; S 7111; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE; TRYPTOPHAN 2,3 DIOXYGENASE INHIBITOR; UNCLASSIFIED DRUG; FLUORESCENT DYE; MOLECULAR LIBRARY;

ARTICLE; BREAST CANCER CELL LINE; CANCER IMMUNOTHERAPY; CATABOLISM; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FLUORESCENCE; GLIOBLASTOMA CELL LINE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOLECULE; NEUROLOGIC DISEASE; PROTEIN EXPRESSION; SYNTHESIS; ANTAGONISTS AND INHIBITORS; CATALYSIS; CELL LINE; DIAGNOSTIC USE; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; IC50; METABOLISM; MOLECULAR LIBRARY; PROCEDURES;

CATALYSIS; CELL LINE; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; ENZYME ASSAYS; ENZYME INHIBITORS; FLUORESCENT DYES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INHIBITORY CONCENTRATION 50; SMALL MOLECULE LIBRARIES; TRYPTOPHAN; TRYPTOPHAN OXYGENASE;

EID: 84908895319     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057114536616     Document Type: Article

References (34)

1. Munn D. H., Zhou M., Attwood J. T., et al. Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism. Science. 1998 ; 281: 1191-1193
2. Schutz G., Feigolson P.. Purification and Properties of Rat Liver Tryptophan Oxygenase. J. Biol. Chem. 1975 ; 247: 5237-5332
3. Uyttenhove C., Pilotte L., Théate I., et al. Evidence for a Tumoral Immune Resistance Mechanism Based on Tryptophan Degradation by Indoleamine 2,3-Dioxygenase. Nat. Med. 2003 ; 9: 1269-1274
4. Brandacher G., Perathoner A., Ladumer R., et al. Prognostic Value of Indoleamine 2,3-Dioxygenase Expression in Colorectral Cancer: Effect on Tumor-Infiltrating T Cells. Clin. Cancer Res. 2006 ; 12: 1144-1151
5. Ino K., Yoshida N., Kajiyama H., et al. Indoleamine 2,3-Dioxygenase Is a Novel Prognostic Indicator for Endometrial Cancer. Br. J. Cancer. 2006 ; 95: 1555-1561
6. Cady S. G., Sono M.. 1-Methyl-DL-Tryptophan, β-(3-Benzofuranyl)-DL-Alanine (the Oxygen Analog of Tryptophan), and β-[3-Benzo(b)thienyl]-DL-Alanine (the Sulfur Analog of Tryptophan) Are Competitive Inhibitors for Indoleamine 2,3-Dioxygenase. Arch. Biochem. Biophys. 1991 ; 291: 326-333
7. Muller A. J., DuHadaway J. B., Scott Donover P., et al. Inhibition of Indoleamine 2,3-Dioxygenase, an Immunoregulatory Target of the Cancer Suppression Gene Bin1, Potentiates Cancer Chemotherapy. Nat. Med. 2005 ; 11: 312-319
8. Zeng J., Cai S., Yi Y., et al. Prevention of Spontaneous Tumor Development in a Ret Transgenic Mouse Model by Ret Peptide Vaccination with Indoleamine 2,3-Dioxygenase Inhibitor 1-Methyl Tryptophan. Cancer Res. 2009 ; 69: 3963-3970
9. Yue E. W., Douty B., Wayland B., et al. Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with In Vivo Pharmocodynamic Activity and Efficacy in a Mouse Melanoma Model. J. Med. Chem. 2009 ; 52: 7364-7367
10. Doluši E., Frédérick R.. Indoleamine 2,3-Dioxygenase Inhibitors: A Patent Review (2008-2012). Exp. Opin. Ther. Patents. 2013 ; 23: 1367-1380
11. Pilotte L., Larrieu P., Stroobant V., et al. Reversal of Tumoral Immune Resistance by Inhibition of Tryptophan 2,3-Dioxygenase. Proc. Natl. Acad. Sci. U. S. A. 2012 ; 109: 2497-2502
12. Opitz C. A., Litzenburger U. M., Sahm F., et al. An Endogenous Tumour-Promoting Ligand of the Human Aryl-Hydrocarbon Receptor. Nature. 2011 ; 478: 197-203
13. Vécsei L., Szalárdy L., Fülöp F., et al. Kynurenines in the CNS: Recent Advances and New Questions. Nat. Rev. Drug Discov. 2013 ; 12: 64-82
14. Zwilling D., Huang S. Y., Sathyasaikumar K. V., et al. Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration. Cell. 2011 ; 145: 863-874
15. Wu W., Nicolazzo J. A., Wen L., et al. Expression of Tryptophan 2,3-Dioxygenase and Production of Kynurenine Pathway Metabolites in Triple Transgenic Mice and Human Alzheimer's Disease Brain. PLoS One. 2013 ; 8: e59749
16. Guidetti P., Bates G. P., Graham R. K., et al. Elevated Brain 3-Hydroxykynurenine and Quinolinate Levels in Huntington Disease Mice. Neurobiol. Dis. 2006 ; 23: 190-197
17. van der Goot A. T., Zhu W., Vázquez-Manrique R. P., et al. Delaying Aging and the Aging-Associated Decline in Protein Homeostasis by Inhibition of Tryptophan Degradation. Proc. Natl. Acad. Sci. U. S. A. 2012 ; 109: 14912-14917
18. Madge D. J., Hazelwood R., Iyer R., et al. Novel Tryptophan Dioxygenase Inhibitors and Combined Tryptophan Dioxygenase/5-HT Reuptake Inhibitors. Bioorg. Med. Chem. Lett. 1996 ; 6: 857-860
19. Röhrig U. F., Majjigapu S. R., Grosdidier A., et al. Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition. J. Med. Chem. 2012 ; 55: 5270-5290
20. Matin A., Streete I. M., Jamie I. M., et al. A Fluorescence-Based Assay for Indoleamine 2,3-Dioxygenase. Anal. Biochem. 2006 ; 349: 96-102
21. Lu C., Lin Y., Yeh S. R.. Inhibitory Substrate Binding Site of Human Indoleamine 2,3-Dioxygenase. J. Am. Chem. Soc. 2009 ; 131: 12866-12867
22. Klockow J. L., Glass T. E.. Development of a Fluorescent Chemosensor for the Detection of Kynurenine. Organic Lett. 2013 ; 15: 235-237
23. Tomek P., Palmer P. D., Flanagan J. U., et al. Formation of an N-Formylkynurenine-Derived Fluorophore and Its Use for Measuring Indoleamine 2,3-Dioxygenase 1 Activity. Anal. Bioanal. Chem. 2013 ; 405: 2515-2524
24. Todorovski T., Fedorova M., Hennig L., Hoffmann R.. Synthesis of Peptides Containing 5-Hydroxytryptophan, Oxindolylalanine, N-Formylkynurenine and Kynurenine. J. Pept. Sci. 2011 ; 17: 256-262
25. Doluši E., Larrieu P., Moineaux L., et al. Tryptophan 2,3-Dioxygenase (TDO) Inhibitors: 3-(2-Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators. J. Med. Chem. 2011 ; 54: 5320-5334
26. Eguchi N., Watanabe Y., Kawanishi K., et al. Inhibition of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase by β-Carboline and Indole Derivatives. Arch. Biochem. Biophys. 1984 ; 232: 602-609
27. Kumar S., Jaller D., Patel B., et al. Structure Based Development of Phenylimidazole-Derived Inhibitors of Indoleamine 2,3-Dioxygenase. J. Med. Chem. 2008 ; 51: 4968-4977
28. Sugimoto H., Shun-ichiro O., Otsuki T., et al. Crystal Structure of Human Indoleamine 2,3-Dioxygenase: Catalytic Mechanism of O2 Incorporation by a Heme-Containing Dioxygenase. Proc. Natl. Acad. Sci. U. S. A. 2006 ; 103: 2611-2616
29. Yamamoto S., Hayaishi O.. Tryptophan Pyrrolase of Rabbit Intestine. J. Biol. Chem. 1967 ; 242: 5260-5266
30. Takikawa O., Kuroiwa T., Yamazaki F., Kido R.. Mechanism of Interferon-γ Action: Characterization of Indoleamine 2,3-Dioxygenase in Cultured Human Cells Induced by Interferon-γ and Evaluation of the Enzyme-Mediated Tryptophan Degradation in Its Anticellular Activity. J. Biol. Chem. 1988 ; 263: 2041-2048
31. Uitdehaag J. C. M., de Roos J. A. D. M., van Doornmalen A. M., et al. Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use. PLoS One. 2014 ; 9: e92146
32. Travers M. T., Gow I. F., Barber M. C., et al. Indoleamine 2,3-Dioxygenase and L-Tryptophan Transport in Human Breast Cancer Cells. Biochim. Biophys. Acta. 2004 ; 1661: 106-112
33. Metz R., DuHadaway J. B., Kamasani U., et al. Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound d-1-Methyl-Tryptophan. Cancer Res. 2007 ; 67: 7082-7087
34. Liu X., Shin N., Koblish H. K., et al. Selective Inhibition of IDO1 Effectively Regulates Mediators of Antitumor Immunity. Blood. 2010 ; 115: 3520-3530